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Background: Carotid angioplasty and stenting (CAS) with cerebral embolic protection is a safe alternative to carotid
endarterectomy in high-risk patients. Among the various systems proposed for cerebral protection, transcervical CAS
avoids crossing the lesion without protection and eliminates the complications associated with transfemoral access. This
study analyzes our experience and the results obtained with a transcervical stenting technique for carotid revasculariza-
tion.
Methods: From January 2005 to June 2006, 62 CASwere performed in our center in high-risk patients with>70% stenosis
(38.7% had a previous neurologic event and 61.3% were asymptomatic). The indications for CASwere severe heart disease
(45.1%), severe pulmonary disease (6.4%), paralysis of the contralateral laryngeal nerve (6.4%), recurrent stenosis (3.2%),
and high carotid lesion (1.6%). Twenty-one patients were >80 years old. A complete neurologic examination was
performed by a stroke neurologist in all patients before and after stenting. The protection system used was carotid flow
reversal by transcervical access. Transcranial Doppler monitoring was done during the procedure in 35 patients. We
analyzed technical success, the presence of high-intensity transient signals during the procedure, neurologic morbidity
and mortality at 30 days and 6 months, and stent patency at 6 months (range, 1 to 18 months). Technical success was
96.8%. Perioperative high-intensity transient signals were observed in two patients (5.7%). In the immediate postoper-
ative period, one patient had a transient ischemic attack of the anterior cerebral artery and another had a stroke, with
contralateral hemiplegia. At 48 hours after discharge, a third patient returned to the hospital with a severe cerebral
hemorrhage that required surgical drainage; hence, neurologic morbidity was 4.9%. There were no deaths at 6 months.
Among the total, 98.4% of the stents remained patent, two showed restenosis of 50% to 70%, and one restenosis of>70%.
No patients presented a neurologic event during the follow-up.
Conclusions: Transcervical carotid artery stenting with flow reversal cerebral protection is a relatively simple, safe
technique that avoids instrumentation of the aortic arch and crossing the target lesion without protection. It is less
expensive than techniques requiring a filter device and provides excellent outcome with an acceptable incidence of
complications. ( J Vasc Surg 2007;46:49-54.)Cerebral embolization is the main neurologic compli-
cation that can occur during carotid stenting. Although no
randomized controlled clinical trials have been conducted
to demonstrate the benefits of cerebral protection during
this procedure, current recommendations strongly support
its use because of the associated reduction in the incidence
of neurologic events.1 Among the available systems for
cerebral protection, the most extensively used is a distal
filter device placed with a transfemoral approach.
Nevertheless, this technique has several drawbacks, the
most important being that it does not ensure complete
cerebral protection. Instrumentation of the aortic arch and
the internal carotid lesion is performed without protection;
in addition, there is no firm evidence that use of the filter
will completely eliminate microembolization once the de-
vice is placed, as seen in studies using transcranial Doppler
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doi:10.1016/j.jvs.2007.02.070(TCD) monitoring.2 Furthermore, femoral puncture can
have associated complications, the procedure is complex
(long duration and considerable contrast requirements),
and the filter devices increase the cost. The recently pub-
lished Endarterectomy Versus Angioplasty in Patients With
Symptomatic Severe Carotid Stenosis (EVA-3S) study,3 a
randomized, multicenter, noninferiority trial that com-
pared stenting with a distal filter for cerebral protection vs
endarterectomy, also reported premature discontinuation
of the trial for safety and futility reasons after 527 patients
had been included.
In contrast, systems for cerebral protection that involve
proximal common carotid artery occlusion and establish-
ment of flow reversal in the internal carotid artery offer an
important advantage: cerebral protection is established be-
fore crossing the lesion, which is one of the most emboli-
genic maneuvers in carotid stenting. The use of a trans-
femoral route to establish flow reversal presents the
drawbacks related to the femoral access. Even so, this
technique seems to reduce the presence of microemboli
during carotid stenting and thereby increases the safety of
the procedure.4
An alternative technique that avoids many of these
problems is carotid artery flow reversal by proximal carotid
occlusion and establishment of an arteriovenous shunt
through the transcervical approach, as described by Criado
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the aortic arch but also decreases the complexity and cost of
the procedure. This study analyzed our experience with
transcervical carotid angioplasty and stenting (CAS) with
carotid flow reversal for cerebral protection.
PATIENTS AND METHODS
From January 2005 to June 2006, we performed 62
CAS procedures in cases of carotid stenosis 70%, using
transcervical access and carotid flow reversal for cerebral
protection. Patients in whom carotid revascularization was
indicated and who were at high risk for carotid endarterec-
tomy (CEA) according to the Stenting and Angioplasty
with Protection in Patients at High Risk for Endarterec-
tomy (SAPPHIRE)6 criteria were prospectively and con-
secutively included in the study. All patients gave informed,
written consent for participation. Results were retrospec-
tively analyzed to determine outcomes.
The grade of carotid stenosis, presence of extensive
calcifications, and morphometry of the lesion were deter-
mined by Doppler ultrasound on a Philips HD 11 unit
(Bothell, Wash). Magnetic resonance angiography (MRA)
was used to assess the brain parenchyma, morphology of
the lesion, presence of vessel tortuousities, and the status of
intracerebral circulation. All patients underwent a preoper-
ative TCD study (PMD-100, Spencer Technologies, Seattle,
Wash) to evaluate the cerebral vascular reactivity (consid-
ered exhausted when the mean velocity in the middle
cerebral artery increases 20% after 20 seconds of apnea),7
the presence of high-intensity transient signals (HITS), and
the existence of associated intracranial lesions. All patients
underwent a complete neurologic examination before and
after the procedure by a stroke neurologist, who was also
present during all the procedures.
In the last 35 patients in the series, TCD monitoring
was performed during revascularization to determine the
presence of HITS and variations in the middle cerebral
artery flow velocity and pulsatility index at the start and
completion of the procedure, immediately after clamping
of the common carotid artery and a few minutes after
clamping. This was done to analyze the mechanisms of
cerebral compensation. These data are presented in a sepa-
rate article8 that mainly analyzes intracerebral hemody-
namic aspects but not technical issues and clinical outcome,
which are the subject of the present study.
All patients were prescribed acetylsalicylic acid
(300 mg/d) and clopidogrel (75 mg/d) for at least 4 days
before the procedure. In cases of noncompliance with this
treatment, a 300-mg loading dose of clopidogrel was ad-
ministered 24 hours before the procedure.
The surgical technique described by Criado et al9 was
used in all patients. Under local anesthesia, a vertical mini-
incision was made in the base of the neck to access the
proximal common carotid artery, which was controlled by a
vessel loop. After dissection of the internal jugular vein, a
shunt was created between the carotid and jugular vein by
placing an 8F introducer sheath (Super Arrow Flex; Arrow
International, Reading, Pa) in each vessel and connectingthe introducers with a 15-cm tube (Figs 1 and 2). Under
systemic heparinization, the common carotid artery was
occluded, and retrograde flow was established in the inter-
nal carotid artery with fluoroscopic control to ensure
proper function of the shunt. TCD monitoring confirmed
correct flow inversion in the intracranial portion of the
Fig 1. Under local anesthesia, a vertical mini-incision was made
in the base of the neck to access the proximal common carotid and
the internal jugular vein. A shunt was created between the carotid
and jugular vein by placing an 8F introducer sheath in each vessel
and connecting the introducers with a short tube.
Fig 2. A shunt was created between the carotid artery (1) and
jugular vein (2) by placing an 8F introducer sheath (3) in each
vessel and connecting the introducers with a tube. The common
carotid artery was occluded (4), and retrograde flow was
established.internal carotid artery in patients in whom it was possible to
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any of these cases. Angiography in anteroposterior and
oblique views was performed to quantify the stenosis.
Next, a 0.014-inch (190 cm) Spartacore (Guidant,
Santa Clara, Calif) or 0.014-inch (180 cm) Platinum Plus
ST guidewire (Boston Scientific, Natick,Mass) was inserted
in a 40-cm long Berenstein 4F catheter (Angiodynamics,
Queensbury, NY), and the internal carotid artery lesion was
crossed through the sheath placed in the common carotid
artery. Once the proximal guidewire reached the carotid
siphon, the stent (Acculink, Guidant; or Carotid Wallstent
Monorail, Boston Scientific) was deployed and dilated with
a 5-mm  30-mm or 6-mm  30-mm Viatrac Plus
(Guidant) or a 5-mm 20-mm or 6-mm  20-mm Ultra-
soft angioplasty balloon (Boston Scientific).
Slow, manual aspiration (20 mL) was done before the
clamp was released, and an angiographic study was done to
assess the technical outcome and investigate possible com-
plications. Atropine (0.5 to 1 mg) was injected in the case
of important bradycardia, and intra-arterial nitroglycerin
(100 to 200 g) was used when spasm of the distal carotid
occurred. After withdrawal of the introducers, the puncture
sites were closed with 5-0 polypropylene sutures.
Double antiplatelet therapy (aspirin and clopidogrel)
was maintained for the first 30 days; thereafter, clopidogrel
(75 mg/d) was prescribed indefinitely. Clinical and Doppler
ultrasound follow-up studies were performed at 24 hours,
1, 3, 6, and 12 months, and yearly thereafter.
RESULTS
The mean age of the participating patients was 76.5
years (range, 56 to 92 years) and 52 (83.9%) weremen. The
distribution of cardiovascular risk factors and associated
diseases is summarized in Table I. The main indications for
carotid stenting were elevated cardiac risk in 28 patients
(45.1%), of whom 4 had prior myocardial revascularization;
severe obstructive pulmonary disease in 4 (6.4%), contralat-
eral laryngeal nerve paralysis in 4 (6.4%), recurrent stenosis
Table I. Epidemiologic and clinical variables of the
patients treated
N %
Age, mean years (range) 76.5 (56-92)
Sex (male) 52 83.9
Hypertension 50 80.6
Diabetes mellitus 21 33.9
Hypercholesterolemia 34 54.8
Smoking 12 19.4
Ischemic heart disease 38 61.3
Pulmonary disease 19 30.6
Renal failure 0 0
Symptomatic 24 38.7
Contralateral stenosis 50% 20 32.7
Intracranial lesion 24 38.7
Decreased or exhausted hemodynamic
reserve
12 19.3after CEA in 2 (3.2%), prior cervical radiotherapy in 2(3.2%), distal internal carotid lesion in 1 (1.6%), and age
80 years in 21 (33.8%). None of the patients treated had
creatinine values 1.5 mg/dL. Twenty-four patients
(38.7%) presented with symptomatic70 % carotid steno-
sis, of whom three had amaurosis fugax, 11 had hemi-
spheric transient ischemic attack (TIA), and 10 had previ-
ous ipsilateral stroke.
No stenosis was present in the contralateral carotid
artery in 16 patients (25.8%), and in the remaining patients,
stenosis was 30% to 50% in 16 (25.8%), 50% to 70% in seven
(11.3%), and 70% in six (9.6%). Seven (11.3%) had oc-
clusion of the contralateral internal carotid artery. The
contralateral carotid had been previously revascularized in
10 patients (16.1%). In the TCD study before carotid
stenting, an intracranial artery lesion was detected in 24
patients (38.7%), HITS in one (1.6%), and a decreased or
exhausted cerebral vascular reactivity in 12 (19.3%). All
patients except one received the appropriate antiplatelet
therapy before revascularization.
The mean duration of the procedure was 50 minutes
(range, 30 to 60 minutes), and the mean flow reversal time
was 15.1 minutes (range 5 to 36 minutes). The mean
volume of contrast used was 36 mL (range, 10 to 100 mL),
and mean duration of fluoroscopy was 7.4 minutes (range,
3 to 19 minutes). The arteriographic control showed flow
reversal in all cases. Balloon occlusion of the external ca-
rotid artery was not performed in any patient. Predilation of
the lesion with 3-mm to 4-mm  2-cm balloons (Viatrac
Plus, Guidant) was performed in five patients (8.3%).
The self-expanding stents used were 6-mm 8-mm
30-mm, 6-mm  8-mm  40-mm, 7-mm  10-mm 
30-mm, or 7-mm 10-mm 40-mm Acculink (Guidant)
in 33 cases (54%), and 28% received an 8-mm  29-mm,
9-mm  40-mm, 10-mm  24-mm or 10-mm  37-mm
Carotid Wallstent (Boston Scientific). Postangioplasty
dilation was done in all cases.
Significant distal internal carotid spasm was observed in
two patients, and was resolved successfully with intra-arterial
nitroglycerin. Transient bradycardia in response to postan-
gioplasty dilation was observed in nine cases (14.7%). One
patient presented persistent hypotension during the first 12
hours and required noradrenaline infusion.
The procedure was successfully completed in 60 of the
62 patients, yielding a technical success rate of 96.8%. In
one patient, the procedure could not be performed because
it was impossible to cross the very extensive, preocclusive
internal carotid lesion. The patient’s clinical condition was
such that the risk of surgery was acceptable; hence, CEA
was done. In the other patient, a major dissection was seen
in the common carotid artery after the stent placement was
completed. Given its proximity to the introducer sheath, it
did not seem advisable to attempt endovascular treatment,
and a bypass from the common carotid artery to the distal
internal carotid was performed instead. Neither of these
two patients presented neurologic symptoms at the end of
these procedures. None of the remaining patients had
residual stenosis 30%.
JOURNAL OF VASCULAR SURGERY
July 200752 Matas et alOne patient experienced a TIA of the anterior cerebral
artery territory that recovered 12 hours. Another patient
experienced a stroke with contralateral hemiplegia. A
Doppler ultrasound examination 24 hours after CAS
showed an in-stent thrombosis, and a cerebral computed
tomography (CT) scan showed acute infarction signs in the
middle cerebral artery territory ipsilateral to the revascular-
ized carotid. In agreement with the stroke neurologist, we
did not believe a new attempt of revascularizing this terri-
tory was indicated because of the recent infarction. At 48
hours after hospital discharge, another patient returned
with hemiplegia and aphasia after an episode of intense
headache. A CT scan showed an extensive cerebral hema-
toma that required surgical drainage. Thus, neurologic
morbidity was 4.9% in this series.
Intolerance to flow reversal was observed in one patient
(1.6%), who lost consciousness a few minutes the common
carotid was clamped. The procedure was extremely rapid in
this case, and the patient recovered without sequelae after
declamping. One large cervical hematoma was observed,
which required surgical drainage (Table II). TCD monitor-
ing during the procedure detected HITS in two of the
studied patients (5.7%) and flow reversal in the anterior
cerebral artery in 28 patients (80%); no patient showed
middle cerebral artery flow reversal. A significant improve-
ment in the middle cerebral artery mean flow velocity and
pulsatility index was observed at completion of the proce-
dure.
The 24-hour Doppler ultrasound examination con-
firmed stent patency in all patients except for the one
mentioned patient (98.4%). In addition, during the first 24
hours, troponin levels were determined every 6 hours in all
patients, and all results were negative.
Patients were discharged from the hospital 48 hours
after the intervention. Median follow-up was 6 months
(range, 1 to 18 months). No deaths or cardiac complica-
tions occurred in the first 30 days. There were two cases of
significant restenosis (50% to 70%) and one restenosis of
70%. None of the patients presented neurologic events in
the stented carotid vascular territory during follow-up.
DISCUSSION
During the last decade, there has been a considerable
rise in the use of endovascular techniques to treat carotid
stenosis and increasing interest in the development and
optimization of the systems used to perform these proce-
Table II. Technical complications, morbidity, and
neurologic complications related with transcervical access
N %
Technical success 60/62 96.8
Neurologic morbidity 3/62 4.9
Complications
Major (cervical hematoma) 1/62 1.6
Minor 0 0dures. Initial results with this approach were discouragingbecause the morbidity and mortality rates were not compa-
rable with those obtained with CEA. Nevertheless, the
introduction of routine stenting and cerebral protection
systems considerably improved the outcome,10 and current
results are similar to those reported for CEA.6,11,12
No comparative studies are available on the optimal
cerebral protection system for CAS, and the published
results from series using different techniques are similar.
However, studies with TCD have shown that when distal
protection systems are used,13 HITS are detected in most
steps of the procedure. Although the clinical relevance of
these findings remains to be determined, the association
between HITS and the incidence of intraoperative stroke
seems clear. Indeed, a study by Schüter et al14 of CAS
procedures with protection devices found diffusion lesions
indicating ischemia in up to 22.7% of patients when study-
ing the cerebral parenchyma with diffusion-weighted mag-
netic resonance imaging.
In contrast, systems based on internal carotid artery
flow reversal present several advantages compared with the
use of distal protection systems. The Parodi Antiemboli
System (PAES; ArteriA, San Francisco, Calif) transfemoral
flow inversion catheter is the only one that has shown
virtual elimination of the embolization particles in studies
performed in vitro15 and in vivo.16 In our experience with
the first 23 TCD-monitored patients,8 no air or solid
emboli were detected at any phase of the procedure, con-
firming the hypothesis that internal carotid artery flow
inversion offers adequate cerebral protection in most cases.
In the remaining 12 patients monitored with TCD, HITS
were observed in two patients. We believe that monitoring
the shunt by fluoroscopy is fundamental for confirming
reversal of flow, but TCDmonitoring further allows detec-
tion of cases in which the flow reversal does not suffice to
completely eliminate microemboli, resulting in incomplete
cerebral protection.
Without external carotid occlusion, reliable reversed
flow cannot be guaranteed throughout the procedure be-
cause internal carotid stump/back pressure can be quite
low and venous pressure quite high with respiratory varia-
tion and coughing, causing intermittent antegrade internal
carotid artery flow from the higher pressure external carotid
system. Hence, fluoroscopy confirmation of reversed flow
with a contrast injection does not confirm total reverse flow
during the whole procedure. TCD is used to indicate when
manual aspiration is necessary.
In our experience, the patients in whom the external
carotid artery could not be visualized on diagnostic angiog-
raphy once the common carotid was clamped had a greater
probability of presenting HITS. In the two mentioned
patients withHITS, manual transient aspiration was used at
the time the lesion was crossed, at stent deployment, and at
postangioplasty dilation. The disappearance of microem-
boli in the intracranial internal carotid on TCD demon-
strated the efficacy of this maneuver. Therefore, we con-
sider that transient aspiration, which simplifies the
procedure and decreases possible complications, could be
an alternative to balloon external carotid occlusion, as done
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scribed a variation of the technique that combines proximal
occlusion of the common carotid and distal filter placement
with transient aspiration applied during navigation over the
target lesion and before filter deployment. The authors
concluded that this maneuver might decrease the neuroem-
bolic risk of the procedure.
Among the most controversial issues of proximal ca-
rotid occlusion with flow reversal is the patient’s tolerance
of this technique. In the Criado series,5 clamping of the
common carotid artery was well tolerated in 96% of pa-
tients, and only two of the seven patients with contralateral
carotid occlusion did not tolerate clamping. Intolerance
was seen in 3% in the Parodi et al4 study, and all the patients
studied tolerated clamping in the Chang.18 In our experi-
ence, neurologic intolerance during the procedure occurred
in only one patient (1.6%), who had contralateral carotid
occlusion and obliteration of the anterior cerebral artery.
Preoperative evaluation to determine the status of in-
tracranial circulation and the cerebral vascular reactivity by
magnetic resonance angiography and TCD can be an aid to
identify patients who may not tolerate carotid clamping.
We found that patients with an exhausted cerebral vascular
reactivity before the intervention presented poor collateral
flow recruitment, and the middle cerebral artery flow ve-
locity did not gradually increase as a compensatory mech-
anism after common carotid clamping.8 In our opinion, the
two possible options to follow when this occurs are to
remove the common carotid artery clamp and place a distal
filter device, or (when possible) reduce the duration of flow
inversion by performing the procedure quickly.
Neurologic morbidity in the present series was 4.9%
(1 TIA, 1 ischemic stroke in the immediate postoperative
period, and 1 cerebral hematoma), a rate similar to reported
values in other published series.4,5,19 No deaths occurred in
the first 30 days, and even though 45.1% of the patients
presented with severe ischemic heart disease, no myocardial
infarctions occurred among the treated patients. In addi-
tion, given that these were patients at high risk for CEA and
thus excluded from multicenter reference studies, we be-
lieve the neurologic morbidity rate is comparable with that
of conventional surgery.
The main advantages of transcervical CAS are summa-
rized in Table III. One of the greatest advantages of
transcervical access compared with transfemoral access,
whether for flow inversion or for placement of a distal
protection device, is that the aortic arch is not instru-
mented. Performance of an aortic arch arteriogram, cannu-
lation of the brachiocephalic trunk or common carotid, and
insertion of introducer sheaths or catheter guidewires in the
common carotid are necessary steps in the femoral ap-
proach, during which the brain has no protection. These
steps are not required with the transcervical approach.
Another point to be mentioned is the technical failure
rate of up to 5% with the transfemoral route because of
vessel tortuousities and type II or type III aortic arches in
which the carotid arteries cannot be cannulated or reached
because of associated aortoiliac pathology.21 In addition,the volume of contrast and exposure time reported here are
much lower than the volumes required for diagnostic brain
angiographies reported by other authors.22
Finally, the potential for puncture site complications,
which can reach 15% for femoral access, is avoided.5 Cervi-
cal hematoma is probably the most frequent local compli-
cation associated with the transcervical approach, because
this area is well perfused and patients undergoing the
procedure are receiving antiplatelet therapy. Nevertheless,
direct suture of the incisions made for the introducer
sheaths minimizes the possibility of this complication de-
veloping. In the present study, drainage of a cervical hema-
toma was required in only one case in which the procedure
was done on the left side. There was some difficulty in
cannulating the internal jugular vein in this patient, a
problem we have encountered with some frequency when
working in the left side and which we attribute to the
anatomic positioning of the large veins in this region.
In one patient severe dissection of the common carotid
artery was observed at the end of the procedure, which
required a surgical bypass. This patient had severe calcifica-
tion of the proximal common carotid artery; hence, in
agreement with Criado et al5 and Chang et al,18 we believe
this should be one of the contraindications for the use of
this technique.
Technical success was 96.8% in the present study. The
incidence of technical failures in endovascular procedures
for the internal carotid artery varies from 0%5,19,20 to
10%.23 According to Chang et al,18 up to 6% of these are
due to the transfemoral route and, particularly, to the
inability to insert the catheter and guidewire in the com-
mon carotid artery. The transcervical approach simplifies
the procedure, and because access to the target lesion is
shorter, the possibility of successfully completing the pro-
cedure is thus greater.
CONCLUSION
Randomized controlled trials are needed to determine
which cerebral protection system provides optimal perfor-
mance during carotid stenting. In the interim, results from
clinical series can serve as a guide to improve clinical prac-
tice. In our experience, flow reversal using a transcervical
Table III. Advantages of transcervical carotid
angioplasty and stenting
1. Target lesion is not crossed without protection
2. No instrumentation of aortic arch
● Aortic arch types II and III
● Bovine trunk
● Tortuous supra-aortic vessels
3. Avoids difficulties of femoral access
4. Shorter duration of radiation exposure
5. Smaller volume of contrast
6. Shorter duration of procedure
7. Lower costaccess route is a simple, safe method that eliminates the
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target lesion without protection. The short-term and long-
term outcomes are also good and appear comparable with
the reported results for carotid revascularization by endar-
terectomy.
Manuel Quintana from the Section of Neurology of
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the statistical analysis.
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